Page 5 - Early Phase News Today

Investegate announcements from Galapagos NV, Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care

Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts...

AFM13 in combination with NK cells shows very high overall and complete response rates in 41 heavily pre-treated CD30-positive Hodgkin lymphoma (HL) and...

-- 100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors -- -- 27 of 38 (71%) evaluable...

ZURICH, Dec. 8, 2022 /PRNewswire/ -- Anjarium Biosciences AG ("Anjarium"), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announces the appointment

New Division Emphasizes Existing Focus on Scientific Expertise and Consulting...

/PRNewswire/ -- NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, today announced it will present first...

Innate will share preliminary results of the cohort evaluating lacutamab in Sezary syndrome patients post-mogamulizumab from the ongoing TELLOMAK Phase 2 trial Chief Scientific Officer, Eric

/PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to...

Investegate announcements from Syncona Limited, Autolus to present clinical data updates at ASH